Revenue FY2025
$0.0M
Net Income
$(14.0M)
EPS (Basic)
$-1.85
Net Margin
—
ROE
-10.0%
Total Equity
$138.0M
Shares Out
7M
Monopar Therapeutics — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2016–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 5 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
RA Capital Management
RA Capital Management
$61.8M
0.4%
—
Deerfield Management Company
Deerfield Management Company
$30.0M
0.2%
—
Vivo Capital
Vivo Capital
$8.4M
0.1%
—
OrbiMed Advisors
OrbiMed Advisors
$14.6M
0.1%
NEW
Adage Capital Management
Adage Capital Management
$19.4M
0.0%
(32.3%)
Insider Transactions
Reading stored insider transactions…